TY - JOUR
T1 - Corrigendum to “Adrenocortical carcinomas and malignant phaeochromocytomas
T2 - ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annals of Oncology volume 31 (2020) 1476-1490, (S0923753420421076), (10.1016/j.annonc.2020.08.2099)]
AU - ESMO Guidelines Committee
AU - Fassnacht, M.
AU - Assie, G.
AU - Baudin, E.
AU - Eisenhofer, G.
AU - Fouchardiere, C. de la
AU - Haak, H. R.
AU - de Krijger, R.
AU - Porpiglia, F.
AU - Terzolo, M.
AU - Berruti, A.
N1 - Publisher Copyright:
© 2022 European Society for Medical Oncology
PY - 2023/7/1
Y1 - 2023/7/1
N2 - The authors regret that the legend to Fig. 4 of this publication was given incorrectly. The correction is as follows: For “CVD, cyclophosphamide, vincristine, doxorubicin” read “CVD, cyclophosphamide, vincristine, dacarbazine”. The authors would like to apologise for any inconvenience caused.
AB - The authors regret that the legend to Fig. 4 of this publication was given incorrectly. The correction is as follows: For “CVD, cyclophosphamide, vincristine, doxorubicin” read “CVD, cyclophosphamide, vincristine, dacarbazine”. The authors would like to apologise for any inconvenience caused.
UR - http://www.scopus.com/inward/record.url?scp=85144797760&partnerID=8YFLogxK
U2 - 10.1016/j.annonc.2022.12.006
DO - 10.1016/j.annonc.2022.12.006
M3 - Comment/debate
C2 - 36564283
AN - SCOPUS:85144797760
SN - 0923-7534
VL - 34
SP - 631
JO - Annals of Oncology
JF - Annals of Oncology
IS - 7
ER -